tetano
Editor, Senior Moderator
BMC Infect Dis. 2019 Jul 29;19(1):668. doi: 10.1186/s12879-019-4181-2.
[h=1]Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018.[/h] Fu X[SUP]1[/SUP], Zhou Y[SUP]1[/SUP], Wu J[SUP]1[/SUP], Liu X[SUP]1[/SUP], Ding C[SUP]1[/SUP], Huang C[SUP]1[/SUP], Zheng S[SUP]1[/SUP], Vijaykrishna D[SUP]2[/SUP], Chen Y[SUP]3[/SUP], Li L[SUP]4[/SUP], Yang S[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] A severe seasonal influenza epidemic was observed during 2017-2018 in China, prompting questions on clinical characteristics and outcomes of severe cases with influenza.
[h=4]METHODS:[/h] We retrospectively collected clinical data and outcomes of laboratory-confirmed hospitalized patients (severe to critical) during Jan-2011 to Feb-2018 from five hospitals, followed by a systematic analysis of cases from 2017 to 2018 (n = 289) and all previous epidemics during 2011-2017 (n = 169).
[h=4]RESULTS:[/h] In-hospital fatality was over 5-folds higher during the 2017-2018 (p < 0.01) in which 19 patients died (6.6%), whereas only 2 mortalities (1.2%) were observed during 2011-2017. Of the 289 hospitalized in 2017-2018, 153 were confirmed with influenza B virus, 110 with A/H1N1pdm09, and 26 A/H3N2, whereas A/H1N1pdm09 was the predominant cause of hospitalization in previous seasons combined (45%). Fatal cases in 2017-2018 were exclusively associated with either influenza B or A/H1N1pdm09. Our results show that a significant lower proportion of patients aged 14 or greater were treated with oseltamivir, during the 2017-2018 epidemic, and exhibited higher levels of clinical severity.
[h=4]CONCLUSIONS:[/h] In-hospital fatality rate might be significantly higher in the 2017-2018 season in China. A sufficient supply of oseltamivir and antiviral therapy within 48 h from onset could reduce fatality rates.
[h=4]KEYWORDS:[/h] Antiviral therapy; Clinical characteristics; In-hospital fatality rates; Subtype; The 2017?2018 influenza
PMID: 31357951 DOI: 10.1186/s12879-019-4181-2
[h=1]Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018.[/h] Fu X[SUP]1[/SUP], Zhou Y[SUP]1[/SUP], Wu J[SUP]1[/SUP], Liu X[SUP]1[/SUP], Ding C[SUP]1[/SUP], Huang C[SUP]1[/SUP], Zheng S[SUP]1[/SUP], Vijaykrishna D[SUP]2[/SUP], Chen Y[SUP]3[/SUP], Li L[SUP]4[/SUP], Yang S[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] A severe seasonal influenza epidemic was observed during 2017-2018 in China, prompting questions on clinical characteristics and outcomes of severe cases with influenza.
[h=4]METHODS:[/h] We retrospectively collected clinical data and outcomes of laboratory-confirmed hospitalized patients (severe to critical) during Jan-2011 to Feb-2018 from five hospitals, followed by a systematic analysis of cases from 2017 to 2018 (n = 289) and all previous epidemics during 2011-2017 (n = 169).
[h=4]RESULTS:[/h] In-hospital fatality was over 5-folds higher during the 2017-2018 (p < 0.01) in which 19 patients died (6.6%), whereas only 2 mortalities (1.2%) were observed during 2011-2017. Of the 289 hospitalized in 2017-2018, 153 were confirmed with influenza B virus, 110 with A/H1N1pdm09, and 26 A/H3N2, whereas A/H1N1pdm09 was the predominant cause of hospitalization in previous seasons combined (45%). Fatal cases in 2017-2018 were exclusively associated with either influenza B or A/H1N1pdm09. Our results show that a significant lower proportion of patients aged 14 or greater were treated with oseltamivir, during the 2017-2018 epidemic, and exhibited higher levels of clinical severity.
[h=4]CONCLUSIONS:[/h] In-hospital fatality rate might be significantly higher in the 2017-2018 season in China. A sufficient supply of oseltamivir and antiviral therapy within 48 h from onset could reduce fatality rates.
[h=4]KEYWORDS:[/h] Antiviral therapy; Clinical characteristics; In-hospital fatality rates; Subtype; The 2017?2018 influenza
PMID: 31357951 DOI: 10.1186/s12879-019-4181-2